CGTX Overview

DBV Technologies Surge: DBV Technologies S.A. experienced a dramatic 61.29% increase in after-hours trading after announcing successful results from its Phase 3 study of the VIASKIN Peanut patch for peanut-allergic children, reigniting investor interest.

Modular Medical Offering: Modular Medical, Inc. saw a modest gain of 3.53% amid ongoing investor analysis of its recent public offering announcement, which includes over 12 million shares priced at an effective cost of $0.38 per share.

Other Small Gains: Several other companies, including Co-Diagnostics, Elutia Inc., and Treace Medical Concepts, posted small increases in after-hours trading, attributed to light-volume activity rather than specific news.

Amylyx Pharmaceuticals Update: Amylyx Pharmaceuticals advanced 4.83% following its recent presentation of early Phase 1 trial data for AMX0114, which showed promising safety and tolerability, with further enrollment expected soon.

Biotech Gains in After-Hours Trading: Several small- and mid-cap biotech and healthcare companies saw significant gains in after-hours trading, driven by corporate updates and financing developments.

SeaStar Medical's Leadership Change: SeaStar Medical's stock rose nearly 10% after the appointment of Michael Messinger as Chief Financial Officer, boosting investor confidence despite no new news.

Cognition Therapeutics' Speculative Buying: Cognition Therapeutics rebounded almost 11% in after-hours trading, likely due to speculative buying interest, following a decline during regular trading hours.

Mesoblast's Revenue Projection: Mesoblast's shares increased after management projected over $30 million in gross revenue for the December quarter, indicating strong demand for its cell therapy product, Ryoncil.

Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.

Market Winning Tools: The platform provides essential tools and information to help traders succeed in the stock market.

Cognition Therapeutics' START Study Enrollment: Cognition Therapeutics has successfully enrolled 540 participants in its Phase 2 START Study, which evaluates the safety and efficacy of zervimesine (CT1812) for treating mild cognitive impairment and early Alzheimer's disease, with results expected after 18 months of treatment.

Collaboration and Support: The study is supported by an $81 million grant from the National Institute of Aging and conducted in partnership with the Alzheimer's Clinical Trials Consortium, highlighting the collaborative effort in Alzheimer's research.

Zervimesine's Unique Mechanism: Zervimesine is an investigational oral drug that targets neurodegenerative diseases by potentially interrupting the toxic effects of harmful proteins in the brain, offering a new treatment avenue for patients who do not respond to existing therapies.

Future Implications for Alzheimer's Treatment: The study aims to explore zervimesine's role in combination therapy for patients already receiving approved monoclonal antibody treatments, potentially expanding treatment options for a broader range of Alzheimer's patients.